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Abstract: OBJECTIVES Options for paediatric aortic valve replacement (AVR) are limited if valve repair
is not feasible. Results of paediatric Ross procedures are inferior to adult Ross results, and mechanical
AVR imposes constant anticoagulation with the inherent risks. METHODS The study design was a
prospective, multicentre follow-up of all paediatric patients receiving decellularized aortic homografts
(DAHs) for AVR in 8 European centres. RESULTS A total of 106 children (77 boys) were operated
(mean age 10.1 ± 4.8 years, DAH diameter 20.5 ± 3.8 mm). A total of 60 (57%) had undergone previous
surgical interventions: 34 with 1, 15 with 2 and 11 with ฀3. There was one early death in a 12-year-old
girl, who underwent her fourth aortic valve operation, due to intracerebral haemorrhage on extracorporeal
membrane oxygenation after coronary reimplantation problems following 3-sinus reconstruction 1 year
earlier. One 2-year-old patient died due to sepsis 2 months postoperatively with no evidence for endo-
carditis. In addition, a single pacemaker implantation was necessary and a 2.5-year-old girl underwent
successful HTx due to chronic myocardial failure despite an intact DAH. After a mean follow-up of 3.30 ±
2.45 years, primary efficacy end points mean peak gradient (18.1 ± 20.9 mmHg) and regurgitation (mean
0.61 ± 0.63, grade 0-3) were very good. Freedom from death/explantation/endocarditis/bleeding/stroke
at 5 years was 97.8 ± 1.6/85.0 ± 7.4/100/100/100% respectively. Calculated expected adverse events
were lower for DAH compared to cryopreserved homograft patients (mean age 8.9 years), lower than in
Ross patients (9.4 years) and in the same range as mechanical AVR (12.8 years). CONCLUSIONS Even
though the overall number of paediatric DAH patients and the follow-up time span are still limited, our
data suggest that DAHs may present a promising additional option for paediatric AVR.
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OBJECTIVES: Options for paediatric aortic valve replacement (AVR) are limited if valve repair is not feasible. Results of paediatric Ross pro-
cedures are inferior to adult Ross results, and mechanical AVR imposes constant anticoagulation with the inherent risks.
METHODS: The study design was a prospective, multicentre follow-up of all paediatric patients receiving decellularized aortic homografts
(DAHs) for AVR in 8 European centres.
RESULTS: A total of 106 children (77 boys) were operated (mean age 10.1 ± 4.8 years, DAH diameter 20.5 ± 3.8mm). A total of 60 (57%)
had undergone previous surgical interventions: 34 with 1, 15 with 2 and 11 with >_3. There was one early death in a 12-year-old girl, who
underwent her fourth aortic valve operation, due to intracerebral haemorrhage on extracorporeal membrane oxygenation after coronary
reimplantation problems following 3-sinus reconstruction 1 year earlier. One 2-year-old patient died due to sepsis 2months postopera-
tively with no evidence for endocarditis. In addition, a single pacemaker implantation was necessary and a 2.5-year-old girl underwent
successful HTx due to chronic myocardial failure despite an intact DAH. After a mean follow-up of 3.30 ± 2.45 years, primary efficacy end
points mean peak gradient (18.1 ± 20.9mmHg) and regurgitation (mean 0.61 ± 0.63, grade 0–3) were very good. Freedom from death/ex-
plantation/endocarditis/bleeding/stroke at 5 years was 97.8 ± 1.6/85.0 ± 7.4/100/100/100% respectively. Calculated expected adverse
events were lower for DAH compared to cryopreserved homograft patients (mean age 8.9 years), lower than in Ross patients (9.4 years)
and in the same range as mechanical AVR (12.8 years).
CONCLUSIONS: Even though the overall number of paediatric DAH patients and the follow-up time span are still limited, our data suggest
that DAHs may present a promising additional option for paediatric AVR.
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ABBREVIATIONS
AVR Aortic valve replacement
CPB Cardiopulmonary bypass
DAH Decellularized aortic homograft
ECMO Extracorporeal membrane oxygenation
LCx Left circumflex artery
LV Left ventricular
VSD Ventricular septal defect
INTRODUCTION
Options for paediatric aortic valve replacement (AVR) are limited
where aortic valve repair is not feasible. The durability of the
autograft and the biological conduit used for pulmonary valve re-
placement are inferior in paediatric Ross patients compared with
adult Ross patients [1–4]. In addition, the Ross procedure is un-
suitable for some children due to anatomical reasons or previous
surgical procedures [5, 6].
Conventional xenogenic biological aortic valve prostheses in
children frequently undergo early degeneration, sometimes with
rapid increase in valvular gradients, and sudden cardiac death
has been reported in such situations [7, 8]. Mechanical aortic
valves have shown steady improvements over the past decades,
and simple mechanical failure of these prostheses has become a
rare occurrence. Thromboembolic events, however, constitute
still a major limitation for mechanical valves. According to recent
meta-analyses, the annual risk for major thromboembolic events
should be calculated with 0.5–1.0% for children and 1.2–2.3% for
young adults, leading to a substantial life-time risk [9, 10]. In add-
ition, industry currently does not produce sufficient numbers of
small-sized mechanical valves and new technological develop-
ments are lacking. Although new anticoagulants are in the pipe-
line, their potential clinical value for paediatric mechanical AVR is
currently unclear [11].
Decellularized aortic allografts were introduced clinically over
a decade ago for both adult and paediatric patients with
encouraging early clinical results [12, 13]. Decellularized pulmon-
ary homografts showed superior 10-year results in a matched
comparison with conventional cryopreserved homografts and
bovine jugular vein conduits [14]. Recently, we demonstrated the
extent of spontaneous in vivo recellularization in decellularized
allografts, which forms the basis for regeneration and a robust
long-term function [15].
The reduced immunogenicity of decellularized aortic homo-
grafts (DAHs) may in theory lead to better durability than other
biological valve alternatives for paediatric AVR. However, there
also have been reports about significant calcification occurring in
DAH using other proprietary decellularization protocols, which
make prospective long-term follow-up of all DAHs mandatory
[16, 17].
The aim of this study is to present an update on the current
results of paediatric DAH implantation and to compare these
results with contemporary data on the Ross procedure and other
AVR options for children.
MATERIALS AND METHODS
Study setting
The study design was a prospective, multicentre follow-up of all
paediatric patients receiving DAHs for AVR in 8 European centres
(Hannover, Leuven, Leiden, Zürich, Chisinau, Stuttgart, Erlangen,
Vienna).
The primary end points were periprocedural complications,
heart valve dysfunction and repeat procedure for valve-related
dysfunction (surgical or interventional therapy).
Indication for AVR according to the current clinical guidelines
of the European Association for Paediatric Cardiology was the
key inclusion criterion. Children with active endocarditis were
not included.
Approval for this non-interventional follow-up study was
granted by Hannover Medical School ethics committee (no.
1503-2012) at the study outset, and informed consent was
obtained appropriately from all parents.













































































Surgical procedures were performed according to the locally
established standard procedures under cardiopulmonary bypass
(CPB). Postoperatively, patients were recommended aspirin/
acetylsalicylic acid at 2–3mg/kg per day for 3–6months and, in
some adolescent patients, warfarin therapy was recommended
for 2months followed by continued acetylsalicylic acid medica-
tion. All DAH implantations were performed as a root replace-
ment with coronary reimplantation and without significant
reinforcement procedures.
Homograft procurement and processing
Homografts were procured in line with the current European
Directive 2004/23, as amended, via 3 different tissue banks
(European Homograft Bank, Brussels, Dr R. Jashari; German
Society for Tissue Transplantation—DGFG, Hannover, M. Börgel;
EuroTissue Bank, Rotterdam, A. van den Bogaerdt) and shipped
to Hannover for processing at Corlife oHG (www.corlife.eu).
The DAH was authorized by the German competent authority
as a medicinal product: ‘Cell-free aortic heart valve, Arise AV’ (#
PEI.G.11766.01.1). The processing of each homograft comprises
30 different steps using a detergent-based, non-cryopreserva-
tion approach as described previously [14]. Microbiological as-
sessment was performed as a part of the incoming inspection,
both during and after processing with a final 14-day quarantine.
Each individual homograft was assessed histologically following
processing, and the residual dsDNA content was measured be-
fore and after processing prior to final release. Reference samples
of all homografts were stored in accordance with German law for
at least 1 year.
Statistical analysis
Summaries of the numeric data are given as means and standard
deviation or median and interquartile range as appropriate.
Normal distribution of factors was assessed using the
Kolmogorov–Smirnov test. Categorical variables are given as
counts and percentages. The proportion of explanted and dys-
functional grafts over time was calculated, and a peak echocar-
diographic gradient of >_50mmHg and regurgitation >_moderate
was defined as dysfunctional.
Time-related events, such as freedom from explantation and
degeneration, were evaluated according to the Kaplan–Meier
method.
Status observations after DAH implantation were grouped per
postoperative year, and the frequency of each functional status
was calculated group-wise for all respective DAHs. Since the sta-
tus frequencies applied only for non-explanted conduits, these
frequencies were multiplied by the fraction of conduits that were
not explanted by the middle of the relevant year. Hence, the
functional status frequencies presented here refer to all initially
implanted DAH in the respective period.
In the ARISE Registry, we calculated perioperative mortality
and annually reported rates of adverse events such as late death,
reoperation or reintervention, valve degeneration, thrombotic
and bleeding events and endocarditis for all paediatric DAH
implanted to date. DAH data were compared with the results of
recent large-scale meta-analyses for paediatric AVR, which
included studies of 2743 paediatric Ross patients, 696 children
with mechanical AVR and 224 patients undergoing AVR using a
standard cryopreserved homograft [10, 18]. This long-term
extrapolation was performed by simply adding the observed and
reported early adverse events and annual rates of adverse events.
Annual event rates were calculated to the respective event-free
patient fraction. In addition, actual observed adverse paediatric
DAH events are shown in Kaplan–Meier function equivalent ±
95% confidence interval.
We refrained from testing for statistical significance here, as
we compared prospectively collected multicentre data with meta-
analyses summarizing retrospective and single-centre studies.
SPSS 25 (IBM Corporation, Somers, NY, USA) was used for the
analyses.
RESULTS
Perioperative outcome of paediatric decellularized
aortic homografts implantation
A total of 106 paediatric patients (77 males) were operated be-
tween February 2008 and September 2019 with a mean age of
10.1 ± 4.8 years; the follow-up was complete. Forty (38%) patients
underwent previous catheter interventions, and 60 (57%) had
undergone previous surgical interventions (34 with 1, 15 with 2,
11 with >_3 previous operations). The mean implanted DAH diam-
eter was 20.5 ± 3.8mm, and the mean operation duration was
399 ± 129min with a mean CPB time of 246 ± 101min and a
mean cross-clamp time of 154 ± 51min.
There was 1 early death in a 12-year-old girl, who had under-
gone her fourth aortic valve operation. Death was caused by
intracerebral haemorrhage while on extracorporeal membrane
oxygenation (ECMO) support due to coronary reimplantation
problems following a 3-sinus reconstruction 1 year earlier. One
2-year-old patient died due to sepsis 2months postoperatively
with no echocardiographic evidence for endocarditis; an autopsy
was declined by the parents.
In addition, 1 pacemaker implantation was necessary and a
2.5-year-old girl underwent successful HTx due to chronic myo-
cardial failure despite an intact DAH.
In 4 children, there was simultaneous implantation of a decel-
lularized pulmonary homograft during the AVR procedure.
Table 1 provides the study cohort characteristics.
Coronary reimplantation complications
In 4/106 paediatric patients (3.8%) with a mean age of
8.5 ± 4.6 years, problems occurred during coronary reimplanta-
tion. In 3 patients, stent implantations were performed in the
proximal right coronary artery or left coronary artery to remedy
persisting postoperative ECG alteration. One of these 3 patients
died while on ECMO support as described above.
Posterior left ventricular (LV) impairment after CPB led to an A.
mammaria free-graft to the left circumflex artery (LCx) in a 7-
year-old boy, which immediately resolved LV hypo-motility.
Interestingly, a coronary angiography performed 6months later
showed a normal LV function and normal left coronary artery
and LCx. The arterial bypass to the LCx was almost totally
occluded, rendering a temporary LCx perfusion problem by a
thrombus or an intima flap the most likely explanation for the
impairment.
In the 3 surviving patients, normal LV function was observed at























































































Midterm outcome of paediatric decellularized
aortic homografts
After a mean follow-up of 3.30 ± 2.45 years, the primary efficacy
end points of peak gradient (18.1 ± 20.9mmHg) and regurgitation
(mean 0.61 ± 0.63, grade 0–3) were very good. The mean LV ejec-
tion fraction was 62 ± 9%, and the mean aortic valve diameter
was 20.5 ± 3.8mm, with a mean z-score of -0.01 ± 1.49 and a
mean effective orifice area of 2.36 ± 0.84 cm2.
Freedom from death/explantation/endocarditis/bleeding/
stroke at 5 years was 97.8 ± 1.6/85.0 ± 7.4/100/100/100%, respect-
ively. Figure 1 provides freedom from explantation according to
the Kaplan–Meier method and the functional status of all
implanted DAH in children with up to 11 years of follow-up, as
well as the results for the entire DAH cohort, including adults.
Decellularized aortic homografts failure in
paediatric patients
DAH required explantation in 7/106 patients with a mean age of
5.9 ± 5.7 years (vs 10.1 ± 4.8 years, P = 0.03). All of these patients
underwent previous procedures prior to DAH implantation,
including 2 patients with 3 previous surgical procedures.
In a 2.5-year-old patient, LV function, already severely
impaired preoperatively, did not recover despite excellent graft
function and normal coronary blood flow, resulting ultimately in
heart transplantation. The histological results, including the de-
gree of recellularization after 8months, have been published re-
cently [15].
One case of DAH explantation after 4.5 years due to the
development of subvalvular stenosis has also been published
[12].
In a 7-year-old patient, a rapid calcification occurred within
months after implantation and endocarditis was suspected, but
no specific bacteria were identified despite a thorough microbio-
logical work-up [15].
In the remaining 4 patients, valvular degeneration was
observed leading to DAH explantation. Figure 2 shows one of
these patients, a 14-year-old boy with a small, unrepaired ven-
tricular septal defect (VSD). In 2010, he suffered from pancarditis
during a Streptococcus pneumonia infection, which led to multiple
heart valve complications. He subsequently underwent aortic,
pulmonary and tricuspid valve repair and VSD closure in 2010,
mechanical AVR with a 16-mm ATS in 2011, and received a DAH
following stenosis of the ATS valve due to a subvalvular pannus
formation in November 2015. Unfortunately, the DAH developed
early degeneration and calcification, leading to explantation in
November 2017 and replacement by a mechanical valve (On-X
21mm). Histological analysis confirmed extensive calcification
and matrix destruction (Fig. 2).
In the other 3 patients who also underwent multiple surgical
procedures prior to DAH implementation, lesser DAH degener-
ation was observed but extended to the homograft wall and
Table 1: Patient characteristics for the paediatric DAH cohort and the ARISE Registry cohort including all DAHs implanted to date
Paediatric AVR (N = 106) All DAH
(N = 259)
Implantation period (years) 2008–2019 2008–2019
Age at implantation, median (IQR) 10.1 (4.8) 21.3 (11.6–43.8)
Follow-up, median (IQR) 3.40 (1.8–4.9) 2.5 (1.5–4.4)
Total follow-up 350 713
Sex (male), n (%) 77 (73) 176 (68)





Type of previous procedures
1 AVR 11 32
2 AVR 2 7
3 AVR 1 1
Catheter-based intervention 40 48
Aortic valve repair 15 23




Implantation time (min), median (IQR)
Total operation 370 (311–466) 324 (245–423)
Cardiopulmonary bypass 228 (191–289) 174 (130–240)
Cross-clamp 145 (124–181) 127 (99–158)
Latest echocardiography
Aortic annulus (mm), mean (SD) 20.5 (3.8) 22.0 (4.0)
Aortic annulus, z-score, mean (SD) -0.01 (1.49) 0.18 (1.49)
Effective orifice area (cm2), mean (SD) 2.4 (0.8) 2.9 (0.8)
Peak gradient (mmHg), median (IQR) 12 (8–21) 11 (7–17)
Regurgitation (grade 0–3), median (IQR) 0.5 (0–1) 0.5 (0–1)
LV ejection fraction (%), mean (SD) 62.3 (9.1) 62.7 (8.4)
Mean and SD are for normally distributed factors and median and IQR are for factors with no normal distribution.
AVR: aortic valve replacement; DAH: decellularized aortic homografts; IQR: interquartile range; LV: left ventricular; SD: standard deviation.













































































cusps. In one of these patients, a mechanical AVR was performed
during a procedure for mechanical mitral valve replacement due
to progressive mitral stenosis to avoid an additional sternotomy,
although the DAH was only mildly stenotic (29mm peak).
Four of the 7 patients underwent redo AVR procedures with
DAH and showed normal homograft function up to 4 years post-
operatively. Two patients received a mechanical valve at reopera-
tion. There were no mortalities in any of the 6 AVR redo
procedures, and 1 successful HTx was performed.
Figure 3 shows the patient with the longest follow-up after
redo DAH implantation.
A 0.2-year-old boy, following 2 balloon dilatations, underwent
AVR with a 10-mm DAH in 2010 and redo AVR in 2015 with a
17-mm DAH due to subvalvular stenosis leading to aortic regur-
gitation by jet-lesion destruction of 1 cusp. The LV and homo-
graft were functioning normally 4 years after the redo procedure.
Expected adverse events for contemporary aortic
valve replacement options in children
Perioperative and annually reported adverse events, such as
death, reoperation or reintervention, valve degeneration, throm-
botic and bleeding events and endocarditis, were calculated for
conventional cryopreserved allografts (patients mean age
8.9 years), mechanical valves (patients mean age 12.8 years), the
Ross procedure (patients mean age 9.4 years) and DAH (patients
mean age 10.1 ± 4.8 years) to provide an overview of expected
adverse events per patient (Table 2).
Figure 4 shows that according to the limited follow-up data
available so far, DAHs in children perform comparably to the
conventional alternatives of mechanical valves and the Ross pro-
cedure, and better than conventional cryopreserved homografts.
DISCUSSION
The current study adds important information on options for
children undergoing AVR, who are not suitable candidates for
the Ross procedure. Midterm outcome for DAH in children
showed comparable results to those for the Ross procedure and
mechanical AVR, and better results than conventional cryopre-
served homografts in cohorts balanced for age and extent of pre-
vious procedures.
No specific handling issues were experienced during DAH im-
plantation in a multicentre setting. Early mortality rates were
lower with DAH than in paediatric Ross procedures (2.2% vs
4.2%, P = 0.3). Coronary reimplantation complications occurred
in 3.8% of the DAH patients, which is comparable to the rates of
6.5% in children and 5% in young adults for intraoperative coron-
ary artery bypass grafting associated with the Ross procedure [10,
18].
We observed progressive degeneration in a subset of 10% of
paediatric patients receiving DAH. In general, children of younger
age were more likely to experience allograft degeneration. The
mean age of the reoperated children was significantly lower with
5.9 vs 10.1 years (P = 0.03) in the whole paediatric DAH cohort.
Younger children requiring AVR often have poorer anatomical
preconditions and have undergone several previous surgical pro-
cedures. As a consequence, residual LV outflow tract obstruction
may occur after AVR and non-laminar flow is likely to influence
the durability of the delicate structures of any biological valve.
Non-laminar flow may also have a negative impact on spontan-
eous recellularization [15].
The potential of DAH for recellularization in children on the
other hand can be illustrated by the case of a 2.4-year-old girl, in
whom DAH was explanted during heart transplantation due to
pre-existing myocardial failure despite normal graft function.
Significant recellularization of the macroscopically normal homo-
graft by non-immunogenic cells was observed 8 months after im-
plantation, resembling 75% of a normal aortic valve [15].
Furthermore, we hypothesize that immunological aspects play
an important role in DAH failure in young children as the mor-
phological and histological examinations of explanted DAH
resembled degeneration observed in conventional cryopreserved
homografts. Although each DAH allograft undergoes extensive
quality control measurements, rendering incomplete decellulari-
zation highly improbable, there appears to be an individual sen-
sitization mechanism at work. This sensitization may be directed
towards the collagen matrix structure of the DAH or towards
remaining antigens within extracellular matrix substances, which
are not removed during the decellularization process [19]. We
have initial unpublished data showing different immune
responses towards different decellularized xenografts by the
same individual. Human immune responses towards different
decellularized allografts are currently under analysis in healthy
controls at our institution, and early data indicate considerable
variance in the individual immune responses towards decellular-
ized pulmonary and aortic homografts. This work has prompted
Figure 1: Freedom from explantation according to the Kaplan–Meier method
and functional status of all implanted DAH in children and for all DAHs, includ-
ing those in adults. Displayed functional status frequencies refer to all DAHs























































































Figure 2: A fourteen-year-old boy 2 years after decellularized aortic homograft implantation following multiple previous procedures due to endocarditis. The com-
puted tomography scan showed a decellularized aortic homograft cusp and wall calcification, which were confirmed at explantation and histologically.
Figure 3: A 0.2-year-old boy, S/P 2  aortic valve balloon valvuloplasty, aortic valve replacement with DAH 10mm in 2010. Intraoperative images at redo aortic valve
replacement in 2015 with a 17-mm DAH due to subvalvular stenosis leading to aortic regurgitation by jet-lesion destruction of 1 cusp. The left ventricle and homo-
graft were functioning normally 4 years after redo. DAH: decellularized aortic homograft; RCA: right coronary artery.













































































the consideration of preoperative allograft matching tests, which
may help to avoid this type of sensitization and hence reduce
reoperation rates in young children.
In 4 of 6 redo AVR within the paediatric DAH cohort, we per-
formed a second DAH implantation following open and thor-
ough consultation with the respective parents.
Allograft wall degeneration and calcification was manageable
intraoperatively including uneventful coronary transfer. All reop-
erations were successful with no mortalities, matching the suc-
cessful results of redo aortic root replacement procedures in
adults [20]. We observed no early degeneration of the second
DAH during the follow-up of up to a maximum of 4 years so far.
While the current results for paediatric DAH are not yet ideal
and despite the limitations of the restricted availability of allog-
rafts, we nonetheless consider that DAH constitutes an additional
therapeutic option in particular for children who have undergone
multiple previous aortic procedures. DAH allows better recon-
struction of the LVOT than a pulmonary autograft. The associated
dilatation of the ascending aorta can be simultaneously treated
using a long DAH, thereby avoiding composite grafts, which are
often more prone to endocarditis. There are also a growing
number of paediatric patients requiring double semilunar valve
replacement, for whom double valve replacement with decellu-
larized allografts represents the only viable biological option [21].
Limitations
The short follow-up currently available for DAH constitutes the
biggest limitation, and long-term tracking of DAH patients will be
mandatory especially in view of the long life expectancy for
paediatric patients.
Moreover, there are a number of limitations to the present
study, including the one-armed study design and the restrictions
inherent in the comparison of prospectively collected multicentre
data with retrospectively conducted single-centre analyses and
meta-analyses based on such reports. A relative strength of the
analysis is the uniquely large size of the comparative groups for
AVR and the age matching of these groups to the DAH cohort,
which allowed direct comparison.
The applicability of the conclusions from this study to other
proprietary decellularization protocols is limited due to potential
Table 2: Observed perioperative mortality and annual adverse events for DAH in children in comparison to reported results of paedi-
atric Ross procedures, mechanical AVR and standard allograft implantation in children
DAH Ross [18] Mechanical [10] Allograft [10]
Early death (%) 0.94 4.19 7.34 12.82
Late mortality (%/years) 0.38 0.54 1.23 1.59
Reoperation and intervention (%/years) 2 3.04 1.07 5.44
Structural valve degeneration (%/years) 2.29 3.25 0.86 2.93
Thrombosis/bleeding (%/years) 0 0.35 1.15 1.99
Endocarditis (%/years) 0.29 0.27 0.45 0.66
AVR: aortic valve replacement; DAH: decellularized aortic homografts.
Figure 4: All paediatric DAHs implanted to date in comparison to recently published meta-analysis data for several AVR options in children. Perioperative and annual
adverse events such as death, reoperation or reintervention, valve degeneration, thrombotic and bleeding events and endocarditis were summarized to provide an ex-
trapolation of expected adverse events per patient in the long term. In addition, actual observed adverse paediatric DAH events are shown in Kaplan–Meier function
equivalent ± 95% CI. Data taken from Etnel et al. [10, 18]. AVR: aortic valve replacement; CI: confidence interval; DAH: decellularized aortic homografts; FU: follow-up;























































































differences in immunogenicity and, consequently, recellulariza-
tion capability.
CONCLUSION
Even though the overall number of paediatric DAH patients and
the follow-up time span are still limited, our data suggest that
DAH may offer a promising additional option for paediatric AVR.
The reported preliminary DAH outcome data in children were
comparable with the results of current paediatric Ross proce-
dures and mechanical AVR, and better than standard cryopre-
served allografts.
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